Orforglipron Promotes Significant Weight Loss Across All Menopausal Stages
New research suggests the oral GLP-1 receptor agonist may help women lose substantial weight before, during, and after menopause.
Why This Study Matters
Weight management becomes increasingly challenging for many women during the menopausal transition. Hormonal changes can contribute to increased body fat, particularly around the abdomen, while making weight loss more difficult.
The new findings suggest that orforglipron may provide an effective treatment option across all stages of menopause, helping women achieve meaningful and sustained weight reduction.
About the Research
Researchers conducted a post-hoc analysis of two major clinical trials:
ATTAIN-1
Included adults with overweight or obesity who did not have type 2 diabetes.
ATTAIN-2
Included adults with overweight or obesity who also had type 2 diabetes.
Female participants were categorized into three groups:
Researchers evaluated changes in body weight, waist circumference, waist-to-height ratio, and the percentage of women achieving clinically significant weight loss after 72 weeks of treatment.
Weight Loss Results in ATTAIN-1
Premenopausal Women
14% weight loss with orforglipron
Compared with only 0.25% with placebo.
Perimenopausal Women
14.38% weight loss with orforglipron
Compared with 1.02% with placebo.
Postmenopausal Women
14.07% weight loss with orforglipron
Compared with 0.62% with placebo.
Weight Loss Results in ATTAIN-2
Similar benefits were observed among women living with type 2 diabetes.
Premenopausal
11.3% weight loss
Placebo: 2.88%
Perimenopausal
8.88% weight loss
Placebo: 1.57%
Postmenopausal
13.62% weight loss
Placebo: 2.0%
More Women Achieved Clinically Significant Weight Loss
The analysis found that the vast majority of women receiving orforglipron achieved meaningful weight-loss milestones.
Orforglipron Group
More than 80% of participants in ATTAIN-1 lost at least 5% of their starting body weight.
Placebo Group
Only about 20% to 25% achieved the same level of weight loss.
Benefits Beyond the Scale
Researchers also observed improvements in measures of abdominal obesity. Women treated with orforglipron were significantly more likely to move into healthier waist-to-height ratio categories compared with those receiving placebo.
Why Menopause Matters in Weight Management
Menopause is often associated with changes in body composition, including increased abdominal fat accumulation and reduced energy expenditure. These changes can make weight management particularly challenging.
The study's results suggest that GLP-1 receptor agonists such as orforglipron may remain highly effective despite these physiological changes.
What Experts Concluded
According to the study authors, the findings demonstrate that orforglipron provides meaningful weight-loss benefits regardless of menopausal stage.
The consistency of results across premenopausal, perimenopausal, and postmenopausal women supports its potential role as an obesity-management treatment option for women throughout adulthood.
What Happens Next?
The promising results add to growing evidence supporting oral GLP-1 receptor agonists as effective treatments for obesity. Additional studies and long-term follow-up data will help clarify durability of weight loss, safety outcomes, and real-world effectiveness.
Bottom Line
New research suggests that orforglipron can produce substantial weight loss in women with obesity or overweight regardless of menopausal status. Women taking the medication lost significantly more weight than those taking placebo, while also showing improvements in waist measurements and body-fat distribution.
• European Association for the Study of Diabetes (EASD) 2026 Annual Meeting, Milan, Italy.
• Study presented by Dr. Andreea Ciudin Mihai, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
• Post-hoc analysis of the ATTAIN-1 and ATTAIN-2 clinical trials evaluating oral GLP-1 receptor agonist orforglipron in women with overweight or obesity.
